Buchumschlag

Navigating the Challenges of Cyclosporine as an Alternative to Rifampicin as an OATP1B Index Inhibitor

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Manthena V. S. Varma, Manoli Vourvahis
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
von: Yi‐An Bi, et al.
Veröffentlicht: (2024)

A Clinical Practice Perspective on the Evaluation of OATP1B1‐associated Drug Interactions
von: Céline K. Stäuble, et al.
Veröffentlicht: (2024)

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions
von: Leila Potzel, et al.
Veröffentlicht: (2026)

Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters
von: Yuki Ujihira, et al.
Veröffentlicht: (2025)

Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study
von: Amedeo De Nicolò, et al.
Veröffentlicht: (2025)

Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
von: Sejung Hwang, et al.
Veröffentlicht: (2024)

Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients
von: Weijie Kong, et al.
Veröffentlicht: (2025)

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action
von: Carolin Zitzmann, et al.
Veröffentlicht: (2026)

Ocular Complications of SGLT ‐2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in T2DM Treatments: A Retrospective Real‐World Cohort Study
von: Lee‐Yuan Lin, et al.
Veröffentlicht: (2025)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
von: Huy X. Ngo, et al.
Veröffentlicht: (2024)

Author Index
Veröffentlicht: (2025)

Keyword Index
Veröffentlicht: (2024)

Keyword Index
Veröffentlicht: (2026)

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
von: Alan Faraj, et al.
Veröffentlicht: (2024)

BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase
von: Aurélie Cabannes‐Hamy, et al.
Veröffentlicht: (2025)

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data
von: Maria J. Alfonso Arvez, et al.
Veröffentlicht: (2025)

Insights Into Aldosterone Regulation Through Pharmacokinetic–Pharmacodynamic Modeling of an Aldosterone Synthase Inhibitor
von: Javiera Cortés‐Ríos, et al.
Veröffentlicht: (2025)

Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation
von: Shin‐Yi Lin, et al.
Veröffentlicht: (2025)

Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement
von: Irina Kareva, et al.
Veröffentlicht: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
von: Titia Q. Ruijs, et al.
Veröffentlicht: (2024)

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis
von: Antonio Tursi, et al.
Veröffentlicht: (2026)

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis
von: Fan Huang, et al.
Veröffentlicht: (2024)

Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase‐4 Inhibitors and Serious Bleeding Events
von: Thanh Phuong Pham Nguyen, et al.
Veröffentlicht: (2024)

Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations
von: Jorge Madrid Paredes, et al.
Veröffentlicht: (2024)

Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test
von: James M. Stevenson, et al.
Veröffentlicht: (2025)

Response to Letters Regarding “Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors”
von: Léonard Laurent, et al.
Veröffentlicht: (2025)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
von: Jatinder Kaur Mukker, et al.
Veröffentlicht: (2025)

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems
von: Janne T. Backman
Veröffentlicht: (2025)

Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis
von: Hongmei Duan, et al.
Veröffentlicht: (2025)

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme
von: Chin Hang Yiu, et al.
Veröffentlicht: (2026)

A Consideration of Exploratory Approaches to Comedications Associated With Immune‐Related Adverse Events during Immune Checkpoint Inhibitor Therapy
von: Yoshihiro Noguchi, et al.
Veröffentlicht: (2025)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
von: Natalia Sauer, et al.
Veröffentlicht: (2026)

Prenatal and Early Childhood Exposure to Antibiotics or Gastric Acid Inhibitors and Increased Risk of Epilepsy: A Nationwide Population‐Based Study
von: Unnur Gudnadottir, et al.
Veröffentlicht: (2025)

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing
von: Ashley N. Springer, et al.
Veröffentlicht: (2025)

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
von: Tania Payo‐Serafín, et al.
Veröffentlicht: (2024)

A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants
von: Xuewen Ma, et al.
Veröffentlicht: (2024)

Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review
von: Patricia Y. Chu, et al.
Veröffentlicht: (2024)

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor
von: Sharif I. Soleman, et al.
Veröffentlicht: (2024)

Toward Developing Alternative Opioid Antagonists for Treating Community Overdose: A Model‐Based Evaluation of Important Pharmacological Attributes
von: Anik Chaturbedi, et al.
Veröffentlicht: (2025)

Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
von: Teng‐Li Lin, et al.
Veröffentlicht: (2026)